(Q36424233)

14 August 2017

0 references

Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations (English)

1 reference

14 August 2017

0 references

R Pencek

1

1 reference

14 August 2017

A Blickensderfer

2

1 reference

14 August 2017

Y Li

3

1 reference

14 August 2017

S C Brunell

4

1 reference

14 August 2017

S Chen

5

1 reference

14 August 2017

language of work or name

1 reference

24 August 2012

1 reference

International Journal of Clinical Practice

14 August 2017

1 reference

14 August 2017

66

1 reference

14 August 2017

11

1 reference

14 August 2017

1021-1032

1 reference

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506736

Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506736

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506736

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506736

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506736

Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized,

30 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.03006.X

Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.03006.X

Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.03006.X

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.03006.X

Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22925173

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1742-1241.2012.03006.X

1 reference

14 August 2017

1 reference

14 August 2017

1 reference